Alembic Pharma Q4 Review: Dolat Capital Upgrades Rating To 'Add', Hikes Target Price Post Inline Results

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

We expect recovery in earnings growth of Alembic Pharmaceuticals Ltd. over FY26E-FY27E, aided by ramp-up in new product launches offsetting US price erosion and recovery in domestic and RoW markets. Decline in working capital days and lower capex will further improve free cash flow over FY26E-27E.

Given the recent correction in stock price there is a decent upside, and therefore, we upgrade our rating to ‘Accumulate’ from Reduce with revised target price of Rs 1,017 at 22x FY27E P/E.

Key risks: Adverse pricing pressure in the US, currency movements and regulatory issues at any of its facilities.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.